Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IXAQF (IXAQF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/24/2025: IXAQF (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit 18.48% | Avg. Invested days 132 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 03/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.60M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 476 | Beta -0.03 | 52 Weeks Range 11.16 - 13.00 | Updated Date 02/17/2025 |
52 Weeks Range 11.16 - 13.00 | Updated Date 02/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -3.91% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 89140398 | Price to Sales(TTM) - |
Enterprise Value 89140398 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 5612490 | Shares Floating 1610376 |
Shares Outstanding 5612490 | Shares Floating 1610376 | ||
Percent Insiders 71.31 | Percent Institutions 11.25 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
IXAQF
Company Overview
History and Background
Ixico PLC (IXAQF) was founded to develop and commercialize technologies for neuroscience. The company focuses on providing imaging and data analytics services for clinical trials in the pharmaceutical industry, particularly for neurological disorders.
Core Business Areas
- Imaging Services: IXAQF offers advanced medical imaging services to quantify the progression of neurological diseases in clinical trials. This includes MRI, PET, and other imaging modalities.
- Data Analytics: The company provides data analytics services to process and analyze imaging data, extracting meaningful insights for drug development.
- Clinical Trial Support: IXAQF offers comprehensive support for clinical trials, including trial design, data management, and regulatory compliance.
Leadership and Structure
IXAQF has a leadership team comprising experienced professionals in the pharmaceutical and medical imaging industries. The organizational structure includes departments focused on research, technology development, and commercial operations.
Top Products and Market Share
Key Offerings
- Trial Tracker: IXAQF's Trial Tracker provides image analytics and biomarker services to sponsors of central nervous system (CNS) clinical trials. The company is used for the quantification of Alzheimeru2019s disease, Parkinsonu2019s disease, Huntingtonu2019s disease, multiple sclerosis and other neurodegenerative diseases. There is no readily accessible market share of Trial Tracker. Competitors include Bioclinica, ERT, and WCG.
- Imaging Data Processing: IXAQF offers data processing and analysis services to extract quantitative measurements from medical images. There is no readily accessible market share of Imaging Data Processing. Competitors include Bioclinica, ERT, and WCG.
Market Dynamics
Industry Overview
The pharmaceutical clinical trial market is experiencing growth, driven by increased investment in drug development for neurological disorders. The rise of AI and machine learning is creating opportunities for faster and more accurate data analysis.
Positioning
IXAQF is positioned as a specialized provider of imaging and data analytics services for neurological clinical trials. Its competitive advantage lies in its expertise in neuroimaging and its proprietary technology platform. Due to the complex quantification of neurological diseases. Their competitive advantage is the speed in analysis which will reduce the time to deliver the drug to market.
Total Addressable Market (TAM)
The global clinical trials market is projected to reach $83 billion by 2027. IXAQF's TAM focuses on the segment of clinical trials related to neurological disorders. IXAQF's positioning helps address this TAM because they are dedicated to specializing in neurological diseases.
Upturn SWOT Analysis
Strengths
- Specialized expertise in neuroimaging
- Proprietary data analytics platform
- Established relationships with pharmaceutical companies
- Strong track record in clinical trial support
Weaknesses
- Reliance on a niche market (neurological disorders)
- Competition from larger CROs
- Limited financial resources compared to larger competitors
Opportunities
- Expansion into new neurological indications
- Development of new AI-based data analytics tools
- Strategic partnerships with technology companies
- Increased demand for imaging-based biomarkers
Threats
- Changes in regulatory requirements for clinical trials
- Technological advancements that could disrupt the market
- Increased competition from new entrants
- Economic downturn affecting pharmaceutical R&D spending
Competitors and Market Share
Key Competitors
- Bioclinica
- ERT
- WCG
Competitive Landscape
IXAQF faces competition from larger CROs with broader service offerings. Its advantage lies in its specialization in neuroimaging and data analytics, but it needs to maintain its technology edge and develop new service offerings to remain competitive.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: IXAQF's historical growth is dependent on securing contracts for clinical trials. It relies heavily on getting contracts for clinical trials.
Future Projections: Future projections are based on industry trends and the company's ability to secure new contracts and expand its service offerings. However, no analyst estimates are available.
Recent Initiatives: Recent initiatives may include investments in new technology platforms, expansion into new geographic markets, or strategic partnerships with other companies.
Summary
IXAQF is a specialized provider in neuroimaging and data analytics for clinical trials, primarily focusing on neurological disorders. Its strengths lie in its expertise and proprietary technology, but it faces challenges from larger competitors and reliance on a niche market. Future growth depends on securing contracts and expanding service offerings. The company has to maintain its technological advantages.
Similar Companies
- Bioclinica
- ERT
- WCG
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Limited financial databases due to availability of information.
Disclaimers:
The information provided is based on available data and may not be exhaustive. Market share estimates are approximate. Financial data may be limited. This analysis is for informational purposes only and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IXAQF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-30 | CEO, CFO, COO & Director Mr. Noah Aptekar | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://www.ixacq.com |
Full time employees - | Website https://www.ixacq.com | ||
IX Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on companies in the technology, media and telecommunications, and information and communication technology industries. The company was incorporated in 2021 and is based in London, United Kingdom. IX Acquisition Corp. operates as a subsidiary of IX Acquisition Sponsor, LLC.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.